Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
Identifieur interne : 000D40 ( PubMed/Corpus ); précédent : 000D39; suivant : 000D41Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
Auteurs : Helen Mcilleron ; Paolo Denti ; Silvia Cohn ; Fildah Mashabela ; Jennifer D. Hoffmann ; Saba Shembe ; Regina Msandiwa ; Lubbe Wiesner ; Sithembiso Velaphi ; Sanjay G. Lala ; Richard E. Chaisson ; Neil Martinson ; Kelly E. DooleySource :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2017.
Abstract
Newborns of HIV-infected mothers are given daily doses of nevirapine to prevent HIV-1 acquisition. Infants born to mothers with TB should also receive TB preventive therapy. TB preventive regimens include isoniazid for 6 months or rifampicin plus isoniazid for 3 months (RH preventive therapy). The effect of concomitant RH preventive therapy on nevirapine concentrations in infants is unknown.
DOI: 10.1093/jac/dkx112
PubMed: 28419277
Links to Exploration step
pubmed:28419277Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.</title><author><name sortKey="Mcilleron, Helen" sort="Mcilleron, Helen" uniqKey="Mcilleron H" first="Helen" last="Mcilleron">Helen Mcilleron</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Denti, Paolo" sort="Denti, Paolo" uniqKey="Denti P" first="Paolo" last="Denti">Paolo Denti</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Cohn, Silvia" sort="Cohn, Silvia" uniqKey="Cohn S" first="Silvia" last="Cohn">Silvia Cohn</name><affiliation><nlm:affiliation>Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mashabela, Fildah" sort="Mashabela, Fildah" uniqKey="Mashabela F" first="Fildah" last="Mashabela">Fildah Mashabela</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Hoffmann, Jennifer D" sort="Hoffmann, Jennifer D" uniqKey="Hoffmann J" first="Jennifer D" last="Hoffmann">Jennifer D. Hoffmann</name><affiliation><nlm:affiliation>Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Shembe, Saba" sort="Shembe, Saba" uniqKey="Shembe S" first="Saba" last="Shembe">Saba Shembe</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Msandiwa, Regina" sort="Msandiwa, Regina" uniqKey="Msandiwa R" first="Regina" last="Msandiwa">Regina Msandiwa</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Wiesner, Lubbe" sort="Wiesner, Lubbe" uniqKey="Wiesner L" first="Lubbe" last="Wiesner">Lubbe Wiesner</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Velaphi, Sithembiso" sort="Velaphi, Sithembiso" uniqKey="Velaphi S" first="Sithembiso" last="Velaphi">Sithembiso Velaphi</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Lala, Sanjay G" sort="Lala, Sanjay G" uniqKey="Lala S" first="Sanjay G" last="Lala">Sanjay G. Lala</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Chaisson, Richard E" sort="Chaisson, Richard E" uniqKey="Chaisson R" first="Richard E" last="Chaisson">Richard E. Chaisson</name><affiliation><nlm:affiliation>Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Martinson, Neil" sort="Martinson, Neil" uniqKey="Martinson N" first="Neil" last="Martinson">Neil Martinson</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Dooley, Kelly E" sort="Dooley, Kelly E" uniqKey="Dooley K" first="Kelly E" last="Dooley">Kelly E. Dooley</name><affiliation><nlm:affiliation>Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28419277</idno><idno type="pmid">28419277</idno><idno type="doi">10.1093/jac/dkx112</idno><idno type="wicri:Area/PubMed/Corpus">000D40</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D40</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.</title><author><name sortKey="Mcilleron, Helen" sort="Mcilleron, Helen" uniqKey="Mcilleron H" first="Helen" last="Mcilleron">Helen Mcilleron</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Denti, Paolo" sort="Denti, Paolo" uniqKey="Denti P" first="Paolo" last="Denti">Paolo Denti</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Cohn, Silvia" sort="Cohn, Silvia" uniqKey="Cohn S" first="Silvia" last="Cohn">Silvia Cohn</name><affiliation><nlm:affiliation>Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mashabela, Fildah" sort="Mashabela, Fildah" uniqKey="Mashabela F" first="Fildah" last="Mashabela">Fildah Mashabela</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Hoffmann, Jennifer D" sort="Hoffmann, Jennifer D" uniqKey="Hoffmann J" first="Jennifer D" last="Hoffmann">Jennifer D. Hoffmann</name><affiliation><nlm:affiliation>Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Shembe, Saba" sort="Shembe, Saba" uniqKey="Shembe S" first="Saba" last="Shembe">Saba Shembe</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Msandiwa, Regina" sort="Msandiwa, Regina" uniqKey="Msandiwa R" first="Regina" last="Msandiwa">Regina Msandiwa</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Wiesner, Lubbe" sort="Wiesner, Lubbe" uniqKey="Wiesner L" first="Lubbe" last="Wiesner">Lubbe Wiesner</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Velaphi, Sithembiso" sort="Velaphi, Sithembiso" uniqKey="Velaphi S" first="Sithembiso" last="Velaphi">Sithembiso Velaphi</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Lala, Sanjay G" sort="Lala, Sanjay G" uniqKey="Lala S" first="Sanjay G" last="Lala">Sanjay G. Lala</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Chaisson, Richard E" sort="Chaisson, Richard E" uniqKey="Chaisson R" first="Richard E" last="Chaisson">Richard E. Chaisson</name><affiliation><nlm:affiliation>Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Martinson, Neil" sort="Martinson, Neil" uniqKey="Martinson N" first="Neil" last="Martinson">Neil Martinson</name><affiliation><nlm:affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Dooley, Kelly E" sort="Dooley, Kelly E" uniqKey="Dooley K" first="Kelly E" last="Dooley">Kelly E. Dooley</name><affiliation><nlm:affiliation>Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The Journal of antimicrobial chemotherapy</title><idno type="eISSN">1460-2091</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Newborns of HIV-infected mothers are given daily doses of nevirapine to prevent HIV-1 acquisition. Infants born to mothers with TB should also receive TB preventive therapy. TB preventive regimens include isoniazid for 6 months or rifampicin plus isoniazid for 3 months (RH preventive therapy). The effect of concomitant RH preventive therapy on nevirapine concentrations in infants is unknown.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28419277</PMID><DateCreated><Year>2017</Year><Month>04</Month><Day>18</Day></DateCreated><DateRevised><Year>2017</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of antimicrobial chemotherapy</Title><ISOAbbreviation>J. Antimicrob. Chemother.</ISOAbbreviation></Journal><ArticleTitle>Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.</ArticleTitle><Pagination><MedlinePgn>2028-2034</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkx112</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Newborns of HIV-infected mothers are given daily doses of nevirapine to prevent HIV-1 acquisition. Infants born to mothers with TB should also receive TB preventive therapy. TB preventive regimens include isoniazid for 6 months or rifampicin plus isoniazid for 3 months (RH preventive therapy). The effect of concomitant RH preventive therapy on nevirapine concentrations in infants is unknown.</AbstractText><AbstractText Label="Patients and methods" NlmCategory="UNASSIGNED">Tshepiso was a prospective case-control cohort study of pregnant HIV-infected women with and without TB whose newborn infants received standard doses of nevirapine for HIV prophylaxis. Infants born to mothers with TB also received RH preventive therapy. Infant plasma nevirapine concentrations were measured at 1 and 6 weeks. The effects of RH preventive therapy on nevirapine disposition were investigated in a population pharmacokinetic model.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">Of 164 infants undergoing pharmacokinetic sampling, 46 received RH preventive therapy. After adjusting for weight using allometric scaling, the model estimated a 33% reduction in nevirapine trough concentrations with RH preventive therapy compared with TB-unexposed infants not receiving concomitant rifampicin and a 30% decline in trough concentrations in a typical infant between day 7 and 35 post-partum.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Rifampicin-based TB preventative treatment reduces nevirapine concentrations significantly in HIV-exposed infants. Although the nevirapine exposures required to prevent HIV acquisition in breastfeeding infants are undefined, given the potential risks associated with underdosing nevirapine in this setting, it is prudent to avoid rifampicin-based preventive therapy in HIV-exposed children receiving prophylactic nevirapine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McIlleron</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denti</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohn</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mashabela</LastName><ForeName>Fildah</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Jennifer D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shembe</LastName><ForeName>Saba</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Msandiwa</LastName><ForeName>Regina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiesner</LastName><ForeName>Lubbe</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velaphi</LastName><ForeName>Sithembiso</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lala</LastName><ForeName>Sanjay G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaisson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinson</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dooley</LastName><ForeName>Kelly E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Tshepiso Study Team</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Antimicrob Chemother</MedlineTA><NlmUniqueID>7513617</NlmUniqueID><ISSNLinking>0305-7453</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>03</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28419277</ArticleId><ArticleId IdType="pii">3737542</ArticleId><ArticleId IdType="doi">10.1093/jac/dkx112</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000D40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28419277
|texte= Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28419277" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |